Holen Sie sich die Stockscreener-App
8.8674
5.28%
-0.4026
Schlusskurs vom Vortag:
$9.27
Offen:
$9.2
24-Stunden-Volumen:
20,637
Relative Volume:
0.32
Marktkapitalisierung:
$86.95M
Einnahmen:
$789.00K
Nettoeinkommen (Verlust:
$5.70M
KGV:
10.95
EPS:
0.81
Netto-Cashflow:
$865.00K
1W Leistung:
-0.23%
1M Leistung:
-3.83%
6M Leistung:
-58.19%
1J Leistung:
-31.41%
1-Tages-Spanne:
$8.84
$9.29
1-Wochen-Bereich:
$8.725
$9.335
52-Wochen-Spanne:
$6.53
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
Firmenname
Seres Therapeutics Inc
Sektor
Branche
Telefon
617 945 9626
Adresse
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
9.07 | 88.86M | 789.00K | 5.70M | 865.00K | 0.81 |
VRTX
Vertex Pharmaceuticals Inc
|
433.56 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.84 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.14 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.59 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.86 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-08 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-21 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-23 | Herabstufung | Goldman | Neutral → Sell |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-03-05 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-11 | Hochstufung | Jefferies | Hold → Buy |
| 2019-04-30 | Eingeleitet | Jefferies | Hold |
| 2018-10-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-08-04 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-01 | Bestätigt | FBR & Co. | Outperform |
| 2016-08-12 | Bestätigt | FBR Capital | Outperform |
| 2016-08-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Bestätigt | H.C. Wainwright | Buy |
| 2016-07-29 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-03-30 | Eingeleitet | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | Guggenheim | Buy |
| 2016-01-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-10-22 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-07-21 | Eingeleitet | Goldman | Neutral |
| 2015-07-21 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Seres Therapeutics Inc Aktie (MCRB) Neueste Nachrichten
MCRB SEC FilingsSeres Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Market Fear: Can Seres Therapeutics Inc weather a recessionDip Buying & Free High Return Stock Watch Alerts - baoquankhu1.vn
MCRB stock declines as Seres Therapeutics pauses SER-155 phase 2 study and shrinks headcount by 30% - MSN
Market Rankings: Is Seres Therapeutics Inc in a bullish channelTrade Volume Summary & Safe Capital Growth Stock Tips - baoquankhu1.vn
Layoff Tracker: Takeda Restructuring Will Affect Workforce, Could Include Layoffs - BioSpace
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Seres Therapeutics cuts 25% of workforce to extend cash runway into Q2 2026 - MSN
Seres Therapeutics (MCRB) price target increased by 31.25% to 21.42 - msn.com
If You Invested $1,000 in Seres Therapeutics Inc (MCRB) - Stock Titan
Seres Therapeutics Sets 2026 Annual Shareholder Meeting Date - The Globe and Mail
MCRB (NASDAQ: MCRB) files Form 144 to resell 8,553 restricted shares - Stock Titan
Kelly Brady Net Worth (2026) - GuruFocus
Seres Therapeutics schedules 2026 annual meeting for June 9 By Investing.com - Investing.com India
Seres Therapeutics schedules 2026 annual meeting for June 9 - Investing.com
Seres Therapeutics sets 2026 annual meeting for June 9; shareholder proposal deadline Mar 26 - TradingView
Seres Therapeutics (MCRB) schedules 2026 meeting, sets proposal deadline - Stock Titan
Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Down 15.4% in February - MarketBeat
MCRB: Canaccord Genuity Maintains Buy Rating with $22 Target | M - gurufocus.com
Seres Therapeutics (NASDAQ:MCRB) Receives Buy Rating from Canaccord Genuity Group - MarketBeat
Exit Recap: Is Seres Therapeutics Inc impacted by rising rates2026 Macro Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Seres Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Seres Therapeutics (NASDAQ:MCRB) Releases Earnings Results, Beats Expectations By $0.50 EPS - MarketBeat
Seres Therapeutics 2025 10-K: $0.8M Revenue, net income $5.70M - TradingView
Seres Therapeutics: Q4 Earnings Snapshot - marketscreener.com
Seres Therapeutics Reports 2025 Results, Highlights Refocused Pipeline - TipRanks
Seres (MCRB) Focuses on Advancing Biotherapeutics Portfolio - GuruFocus
Seres Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Bitget
Seres Therapeutics: Fourth Quarter Earnings Overview - Bitget
Seres Therapeutics (NASDAQ: MCRB) details 2025 profit, cash runway and SER-155 progress - Stock Titan
Seres Therapeutics (MCRB) awards 56,250 stock options to officer - Stock Titan
Seres Therapeutics (MCRB) officer Brady Kelly reports stock holdings - Stock Titan
Seres Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Seres Therapeutics Inc expected to post a loss of $2.11 a shareEarnings Preview - TradingView
Is Seres Therapeutics Incs ROE strong enough2025 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Rally Mode: Should I invest in Seres Therapeutics Inc before earningsGold Moves & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Activity Recap: Should I invest in Seres Therapeutics Inc before earningsWeekly Stock Report & AI Forecasted Stock Moves - baoquankhu1.vn
Aug Action: Does Seres Therapeutics Inc have declining or rising EPSMarket Sentiment Report & Daily Entry Point Alerts - baoquankhu1.vn
Seres Therapeutics (MCRB) director Richard Kender awarded 150,000 stock options - Stock Titan
Seres Therapeutics (MCRB) grants 75,000-share stock option to officer Henn - Stock Titan
The Escalator: Seres Therapeutics, Bavarian Nordic, Moderna and more - Medical Marketing and Media
Seres Therapeutics (MCRB) Projected to Post Earnings on Thursday - MarketBeat
Human Microbiome Therapeutics Market to Reach US$ 5.86 Billion - openPR.com
MCRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Finanzdaten der Seres Therapeutics Inc-Aktie (MCRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Seres Therapeutics Inc-Aktie (MCRB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Shaff Eric D. | Director |
Feb 15 '26 |
Sale |
8.47 |
259 |
2,194 |
11,577 |
| Young Teresa L. | See Remarks |
Feb 15 '26 |
Sale |
8.47 |
75 |
635 |
8,557 |
| DesRosier Thomas | See Remarks |
Feb 15 '26 |
Sale |
8.47 |
78 |
661 |
7,789 |
| Henn Matthew R | See Remarks |
Feb 15 '26 |
Sale |
8.47 |
89 |
754 |
7,677 |
| Young Teresa L. | See Remarks |
Nov 15 '25 |
Sale |
17.30 |
1,042 |
18,027 |
8,401 |
| Shaff Eric D. | Director |
Nov 15 '25 |
Sale |
17.30 |
217 |
3,754 |
11,113 |
| DesRosier Thomas | See Remarks |
Nov 15 '25 |
Sale |
17.30 |
76 |
1,315 |
7,623 |
| Henn Matthew R | See Remarks |
Nov 15 '25 |
Sale |
17.30 |
1,257 |
21,746 |
7,527 |
| Shaff Eric D. | Director |
Aug 18 '25 |
Sale |
16.65 |
217 |
3,613 |
10,609 |
| DesRosier Thomas | See Remarks |
Aug 18 '25 |
Sale |
16.65 |
76 |
1,265 |
7,455 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):